Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Aphelenchoides

ABSTRACT: Aphelenchoides Genome sequencing and assembly

PROVIDER: PRJNA834627 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR19114840_subreads.fastq.gz	Fastqsanger.gz
	SRR19114841_1.fastq.gz	Fastqsanger.gz
	SRR19114841_2.fastq.gz	Fastqsanger.gz
	SRR19114842_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 33

Similar Datasets

Aphelenchoides avenae isolate:uhasgpb2012

Project description:Aphelenchoides avenae isolate:uhasgpb2012 Genome sequencing and assembly

| PRJNA236621 | ENA

Aphelenchoides besseyi isolate:AH1

Project description:Aphelenchoides besseyi isolate:AH1 Genome sequencing and assembly

| PRJNA901680 | ENA

Aphelenchoides fragariae

Project description:Aphelenchoides fragariae overview

| PRJNA182199 | ENA

Aphelenchoides besseyi

Project description:Aphelenchoides besseyi overview

| PRJNA264761 | ENA

Aphelenchoides fragariae

Project description:Aphelenchoides fragariae Transcriptome or Gene expression

| PRJNA233627 | ENA

Aphelenchoides fragariae

Project description:Aphelenchoides fragariae Transcriptome or Gene expression

| PRJNA182116 | ENA

Aphelenchoides avenae

Project description:Aphelenchoides avenae Transcriptome or Gene expression

| PRJNA236622 | ENA

Aphelenchoides besseyi

Project description:Aphelenchoides besseyi Transcriptome or Gene expression

| PRJNA229675 | ENA

Aphelenchoides ritzemabosi strain:China Kunming

Project description:Aphelenchoides ritzemabosi strain:China Kunming Transcriptome or Gene expression

| PRJNA278017 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data